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The Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
The HRS 33rd Meeting will be held in Boston, 9-12/5/12 
 
The ESC Congress will be held in Munich, 25-29/8/2012 
 
TCT Meeting will take place in Miami, 22-26/10/12  
 
HCS Meeting to be held in Athens, 1-3/11/12  
 
AHA 2012 is scheduled for Los Angeles, 3-7/11/12 
  
PARTNER Trial (Cohort B): TAVI Remains Cost-
Effective for Patients with Severe Aortic Stenosis who 
are not Candidates for Surgery 
 
The PARTNER trial randomized patients with 
symptomatic, severe aortic stenosis who were not 
candidates for surgery to transcatheter aortic valve 
implantation (TAVI) (n=179) or standard therapy 
(n=179). Mean costs for the initial TAVI procedure and 
hospitalization were $42,806 and $78,542, respectively. 
Follow-up costs through 12 months were lower with 
TAVI ($29,289 vs $53,621) because of reduced 
hospitalization rates, but cumulative 1-year costs 
remained higher ($106,076 vs $53,621). Projection was 
that over a patient’s lifetime, TAVI would increase 
discounted life expectancy by 1.6 years (1.3 quality-
adjusted life-years-QALY) at an incremental cost of 
$79,837. The incremental cost-effectiveness ratio for 
TAVI was thus estimated at $50,200 per year of life 
gained or $61,889 per QALY gained. The authors 
concluded that TAVI increases life expectancy at an 
incremental cost per life-year gained well within accepted 
values for commonly used cardiovascular technologies. 
(Reynolds MR et al, Circulation 2012;125:1102-1109). 
 
SCAAR Registry: Lower Risk of Stent Thrombosis & 
Restenosis with Unrestricted Use of ‘New-Generation’ 
Drug-Eluting Stents  
 
A total of 94,384 consecutive stent implantations, 
including bare metal (BMS, n=64,631), older generation 
drug-eluting stents (o-DES, n=19,202), and new 
generation DES (n-DES, n = 10 551) were evaluated in 
Sweden. Older generation DES comprised Cypher and 
Cypher Select, Taxus Express and Taxus Liberte, and 
Endeavor Sprint, while n-DES included Endeavor 
Resolute, XienceV, Xience Prime, Promus, and Promus 
Element. A statistically significant lower risk of 
restenosis was shown for n-DES compared with BMS 
[adjusted hazard ratio (HR) 0.29] and o-DES (HR 0.62). 
A lower risk of definite ST was found in n-DES 
compared with BMS (HR 0.38) and o-DES (HR, 0.57). 
The risk of death was significantly lower in n-DES 
compared with o-DES (adjusted HR: 0.77) and BMS 
(adjusted HR: 0.55). The authors concluded that PCI with 
n-DES is associated with a 38% lower risk of clinical 
restenosis, a 43% lower risk of definite ST, and a 23% 
lower risk of death compared with o-DES (Sarno G et al, 
Eur Heart J 2012;33:606-613).  
 
CRT Induced Mechanical Dyssynchrony Presages 
Increased Mortality 
 
Outcome of heart failure patients (n=290) without 
significant baseline left ventricular (LV) dyssynchrony, 
i.e. <60 ms as assessed with tissue Doppler imaging, 
treated with cardiac resynchronization therapy (CRT), 
was compared to that of 290 heart failure patients also 
treated with CRT who showed significant LV 
dyssynchrony (≥60 ms) at baseline. In the group of 
patients without significant LV dyssynchrony, median 
LV dyssynchrony increased from 22 ms at baseline to 40 
ms 48 hours after CRT. The cumulative mortality rates at 
1-, 2-, and 3-year follow-up of patients with LV 
dyssynchrony ≥40 ms at 48 hours after CRT implantation 
were significantly higher when compared with patients 
with LV dyssynchrony <40 ms (10, 17, and 23 vs. 3, 8, 
and 10%, respectively; P <0.001). Finally, the cumulative 
mortality rates at 1-, 2-, and 3-year follow-up of patients 
with baseline LV dyssynchrony were 3, 8, and 11%, 
respectively (P = NS vs patients with LV dyssynchrony 
<40 ms). Induction of LV dyssynchrony after CRT was 
an independent predictor of mortality (hazard ratio: 1.25; 
P = 0.009). The authors concluded that in patients without 
significant LV dyssynchrony, the induction of LV 
dyssynchrony after CRT may confer less favourable long-
term outcome (Auger D et al, Eur Hear J 2012; 33:913-
920).  
 
Catheter Ablation for Atrial Fibrillation: 1 in 20 
Patients Experiences a Complication and 1 in 10 are 
Rehospitalized Within 30 Days  
 
Among 4,156 patients undergoing AF ablation, 5% 
had complications, most commonly vascular, and 9% 
were readmitted within 30 days. Older age, female, prior 
AF hospitalizations, and less hospital experience with AF 
ablation were associated with higher risk of 
complications and/or 30-day readmissions. The rate of 
hospitalization was 38.5% by 1 year and rate of 
readmission form recurrent AF, atrial flutter, and/or 
repeat ablation was 21.7% by 1 year and 29.6% by 2 
years. The authors concluded that complications occurred 
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in 1 of 20 patients undergoing AF ablation, and all-cause 
and arrhythmia related rehospitalizations were common. 
Older age, female gender, prior AF hospitalizations, and 
less hospital procedure experience were associated with a 
higher risk of complications and/or 30-day readmission 
after AF ablation (Shah RU et al, J Am Coll Cardiol 
2012;59:143–149).  
 
Pediatric Cardiomyopathy Registry: Risk 
Stratification for Sudden Cardiac Death (SCD) in 
Children with Dilated Cardiomyopathy (DCM) 
 
Among 1,803 children with a diagnosis of dilated 
cardiomyopathy (DCM), the 5-year incidence rates were 
29% for heart transplantation, 12.1% non-SCD, 4.0% 
death from unknown cause, and 2.4% for SCD. Of 280 
deaths, 35 were SCD, and the cause was unknown for 56. 
The 5-year incidence rate for SCD incorporating a subset 
of the unknown deaths was 3%. Patients receiving 
antiarrhythmic medication were at higher risk of SCD 
(hazard ratio: 3, p = 0.025). Risk stratification based on 
most recent echocardiographic findings had 86% 
sensitivity and 57% specificity. Thirty of 35 SCDs 
occurred in patients who met all these criteria: left 
ventricular (LV) end-systolic dimension z-score >2.6, age 
at diagnosis younger than 14.3 years, and the LV 
posterior wall thickness to end-diastolic dimension ratio 
<0.14. Gender, ethnicity, cause of DCM, and family 
history were not associated with SCD. The authors 
concluded that the 5-year incidence rate of SCD in 
children with DCM is 3%. They proposed the following 
criteria for prophylactic defibrillator (ICD) implantation: 
age at diagnosis younger than 14 years, LV dilation, and 
LV posterior wall thinning (Pahl E et al, J Am Coll 
Cardiol 2012;59:607–615) 
 
Percutaneous Revascularization of Unprotected Left 
Main Remains a Relatively Uncommon Procedure at 
Most U.S. Centers and is Primarily Reserved for 
Those at High Risk for Coronary Bypass  
 
A total of 5,627 patients undergoing percutaneous 
coronary intervention (PCI) for unprotected left main 
coronary artery (LMCA) stenosis at 693 centers within a 
National US Registry (2004-2008) were evaluated. 
Thirty-month mortality and major adverse events with 
drug-eluting vs bare-metal stents were also compared in a 
patient cohort (n = 2,765) aged >65 years. PCI was 
performed in 4.3% of patients with unprotected LMCA 
stenosis. In-hospital mortality rates ranged from 2.9% for 
elective cases to 45.1% for emergent/salvage cases. By 30 
months, 57.9% of the elderly unprotected LMCA PCI 
population experienced death, myocardial infarction, or 
revascularization, and 42.7% died. Patients receiving 
drug-eluting stents (vs bare-metal stents) had a lower 30-
month mortality (hazard ratio-HR: 0.84), but the 
composite of major adverse events were similar. The 
authors concluded that in the US, PCI is performed in 
<5% of patients with unprotected LMCA disease and is 
generally reserved for those at high procedural risk. 
Adverse events are common in elderly patients and are 
related to patient and procedural characteristics, including 
stent type (Brennan JM et al, J Am Coll Cardiol 
2012;59:648–54).  
 
Renal Sympathetic Denervation (RSD) Reduces Left 
Ventricular Mass and Improves Diastolic Function in 
Patients With Resistant Hypertension  
 
A group of 46 patients with resistant hypertension 
underwent bilateral renal sympathetic denervation (RSD), 
and echocardiographic results were compared with those 
of 18 control patients. Besides reduction of systolic and 
diastolic blood pressure (-22.5/-7.2 mm Hg at 1 month 
and -27.8/-8.8 mm Hg at 6 months; p < 0.001), RSD 
significantly reduced mean interventricular septum 
thickness from 14.1 + 1.9 mm to 13.4 + 2.1 mm and 12.5 
+1.4 mm (p = 0.007), and LV mass index from 112.4 + 
33.9 g/m2 to 103.6 + 30.5 g/m2 and 94.9 + 29.8 g/m2 (p < 
0.001) at 1 month and 6 months, respectively. The mitral 
valve lateral E/E΄ decreased after RSD from 9.9 + 4.0 to 
7.9 + 2.2 at 1 month and 7.4 + 2.7 at 6 months (p < 
0.001), indicating reduction of left ventricular (LV) 
filling pressures. Isovolumic relaxation time shortened, 
whereas LV ejection fraction significantly increased after 
RSD (baseline: 63.1 + 8.1% vs. 70.1 + 11.5% at 6 
months, p < 0.001). No significant changes were obtained 
in control patients. The authors concluded that in addition 
to the known effect on blood pressure, it was shown for 
the first time that RSD significantly reduces LV mass and 
improves diastolic function, which might have important 
prognostic implications in patients with resistant 
hypertension at high cardiovascular risk (Brandt MC et 
al, J Am Coll Cardiol 2012;59:901–909).  
 
Atrial Fibrillation (AF) Ablation: Periprocedural 
Dabigatran Use Increases the Risk of Bleeding or 
Thromboembolic Complications Compared With 
Uninterrupted Warfarin Therapy  
 
All 145 patients receiving dabigatran therapy who 
underwent AF ablation on periprocedural dabigatran, 
with the dose held on the morning of the procedure, were 
matched by age, sex, and type of AF with an equal 
number (n=145) of patients undergoing AF ablation with 
uninterrupted warfarin therapy over the same period. The 
mean age was 60 years with 79% being male and 57% 
having paroxysmal AF. Both groups had a similar 
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CHADS2 score, left atrial size, and left ventricular 
ejection fraction. A total of 3 thromboembolic 
complications (2.1%) occurred in the dabigatran group 
and none in the warfarin group (p = NS). Dabigatran led 
to a higher major bleeding rate (6% vs 1%; p = 0.019), 
total bleeding rate (14% vs 6%; p = 0.031), and combined 
bleeding and thromboembolic complication rate (16% vs 
6%; p = 0.009) compared with warfarin. Dabigatran use 
was an independent predictor of bleeding or 
thromboembolic complications (odds ratio: 2.76; p = 
0.01) on multivariate regression analysis. The authors 
concluded that in patients undergoing AF ablation, 
periprocedural dabigatran use significantly increases the 
risk of bleeding or thromboembolic complications 
compared with uninterrupted warfarin therapy 
(Lakkireddy D et al, J Am Coll Cardiol 2012;59: 1168–
1174).   
 
Out-of-Hospital Deaths Within 30 Days Following 
Percutaneous Coronary Intervention (PCI) Occur in a 
Least Expected Group 
 
All 51,695 patients who underwent PCI in New York 
State from January 1, 2007, and December 31, 2007, who 
were discharged alive by December 31, 2007 were 
followed for 30 days after discharge. The in-hospital and 
30-day mortality rate for PCI patients was 0.94%, the in-
hospital mortality rate was 0.56%, and the mortality rate 
for deaths that occurred after discharge within 30 days of 
the procedure was 0.38%. Of the 491 PCI deaths, 199 
(40.5%) occurred after discharge. The percentage of 
short-term (in-hospital or within 30 days) deaths in 
hospitals with >10 short-term deaths ranged from 15% to 
71%. The authors concluded that compared to PCI 
patients dying in-hospital, patients who died <30 days 
after discharge were younger, had better ventricular 
function, were less likely to have had recent myocardial 
infarctions, and were less likely to have had 
postprocedural complications. Most deaths in the 30-day 
group were cardiovascular, and most were cardiac and 
acute. A small percentage were related to chronic cardiac 
or vascular disease (Hannan EL et al, Am J Cardiol 
2012;109:47–52).  
 
Decreased LVEF (<40%) Increases the Risk of Stent 
Thrombosis  
 
Among 5,377 patients undergoing percutaneous 
coronary intervention (PCI), patients with normal left 
ventricular ejection fraction (LVEF) (>50%) were 
compared to those with mild (41% - 50%), moderate 
(25% - 40%), and severe (<25%) decreases in LVEF. 
Patients with abnormal LVEF were older and more 
commonly diabetic and had renal insufficiency and heart 
failure (p <0.001). These patients demonstrated more 
angiographically complex lesions and less frequently 
received a drug-eluting stent. The primary end point (1-
year major adverse cardiac events) was significantly 
increased in patients with lower LVEF (9.7% for normal 
LVEF vs 20.6% for severely decreased LVEF, p <0.001). 
Stent thrombosis occurred more frequently in these 
patients (1.4% for normal LVEF vs 6% for severely 
decreased LVEF, p<0.001), but clinically driven target 
lesion revascularization (TLR) did not significantly 
change across LVEF groups. After adjustment, only 
moderate and severe LVEF decreases (<40%) 
demonstrated an association with major adverse cardiac 
events and stent thrombosis. There was no difference 
between those receiving only a drug-eluting stent or a 
bare-metal stent. The authors concluded that decreased 
LVEF (<40%) is not associated with clinically driven 
TLR but does increase the risk of stent thrombosis (Sardi 
GL et al, Am J Cardiol 2012;109:344–351).  
 
Primary PCI via the Radial Approach is Associated 
with Lower Short-term Mortality  
 
Ten randomized controlled trials involving 3,347 
patients comparing the clinical outcomes of radial and 
femoral approach in primary percutaneous coronary 
intervention (PCI) for ST-elevation myocardial infarction 
(STEMI) were analyzed. The radial approach was 
associated with improved survival (odds ratio 0.53) and 
reduced vascular complications/hematoma (odds ratio 
0.35). A nonsignificant trend was found toward reduced 
major bleeding with the radial approach (odds ratio 0.63). 
The procedural time with the radial approach was longer 
by <2 min (mean difference 1.76 min). The authors 
concluded that in patients undergoing primary PCI, the 
radial approach is associated with lower short-term 
mortality. When feasible, the radial approach should be 
the favored route in primary PCI (Joyal D et al, Am J 
Cardiol 2012;109:813– 818).  
 
Use of Bivalirudin and Closure Devices Reduce the 
Risk for Vascular Complications After Percutaneous 
Coronary Intervention (PCI)  
 
Among 7,718 patients undergoing PCI via femoral 
access, 444 (5.8%) had vascular complications (VCs). 
Compared to those without VCs, patients with VCs were 
older and had more extensive co-morbidities. Severe 
blood loss was most frequent in those who had vascular 
perforation requiring surgical repair or in those who had 
retroperitoneal bleeding. Overall, <25% of patients with 
hematoma had severe blood loss. One-year mortality was 
two-fold higher in patients with minimal or moderate 
hematocrit decrease and three-fold increased in those 
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with severe decreases in hematocrit. Stent thrombosis was 
tripled in patients with VCs and moderate or severe 
decreases in hematocrit. After adjustment, only patients 
with VCs and the greater hematocrit decreases had an 
increased risk for death at 1 year (hazard ratio 1.80). 
Independent predictors of severe hematocrit decrease 
included age, female gender, glycoprotein IIb/IIIa 
inhibitor use, and activated clotting time peak. 
Bivalirudin and closure devices were independently 
associated with less frequent severe bleeding. The authors 
concluded that VCs confer an increased risk for death at 1 
year only when associated with severe blood loss. The 
use of bivalirudin and closure devices seems to reduce the 
risk for such complications (Romaguera R et al, Am J 
Cardiol 2012; 109:75– 81).  
 
In Patients With Out-of-hospital Cardiac Arrest, 
Early Catheterization (<6 Hours) is Associated With 
Improved Survival 
 
Among 240 patients with out-of-hospital cardiac arrest 
caused by ventricular tachycardia or fibrillation, 2 groups 
were evaluated: those receiving acute catheterization 
within 6 hours (<6-hour group, n = 61) and those with 
deferred catheterization at >6 hours or no catheterization 
during the index hospitalization (>6-hour group, n = 179).  
Survival was greater in patients who underwent acute 
catheterization (72% in the <6-hour group vs 49% in the 
>6-hour group, p = 0.001). Percutaneous coronary 
intervention (PCI) was performed in 38 of 61 patients 
(62%) in the <6-hour group and 13 of 170 patients (7%) 
in the >6-hour group (p <0.0001). Neurologic status was 
similar in the 2 groups. A significantly larger percentage 
of patients in the acute catheterization group had 
symptoms before cardiac arrest and had ST-segment 
elevation on ECG after resuscitation. Age, bystander 
cardiopulmonary resuscitation, daytime presentation, 
history of PCI or stroke, and acute ST-segment elevation 
were positively associated with receiving cardiac 
catheterization. The authors concluded that in patients 
with out-of-hospital cardiac arrest, acute catheterization 
(<6 hours) was associated with improved survival (Strote 
JA et al, Am J Cardiol 2012;109:451– 454).  
 
HORIZONS-AMI trial: in Patients With STEMI 
Treated With Primary PCI, Triple Antithrombotic 
Therapy Results in Excess of Bleeding Complications 
and Premature Discontinuation of Coumadin  
 
The outcomes of patients who received triple therapy 
(aspirin, thienopyridine, and coumadin) after primary PCI 
for ST-elevation myocardial infarction (STEMI) were 
assessed in the Harmonizing Outcomes with 
Revascularization & Stents in Acute Myocardial 
Infarction [HORIZONS-AMI] trial. Among the 3,320 
patients having primary PCI, 126 (3.8%) were prescribed 
triple therapy and 3,194 (96.2%) received dual 
antiplatelet therapy. The most frequent indications for 
anticoagulation treatment were a severely reduced left 
ventricular ejection fraction (LVEF) with a large akinetic 
area, atrial fibrillation (23.8% each), and mural thrombus 
(23.0%). The assignment to triple therapy was associated 
with older age, female gender, rhythm disturbances, 
Killip class >1 on admission, lower LVEF, left anterior 
descending artery territory infarcts, and final TIMI flow 
grade <3. Patients treated with triple versus dual therapy 
had comparable short- and long-term ischemic outcomes 
but had significantly increased rates of major bleeding 
during the index hospitalization (17.1% vs 6.5%, p 
<0.0001), resulting in premature discontinuation of 
anticoagulation in 14.3% of those patients. The authors 
concluded that in patients with STEMI treated with 
primary PCI, the combination of aspirin, thienopyridine, 
and coumadin results in an excess of bleeding 
complications and premature discontinuation of 
coumadin. The risk of adding oral anticoagulation to 
patients admitted for STEMI should be carefully 
considered before choosing drug-eluting or bare metal 
stents (Nikolsky E et al, Am J Cardiol 2012;109:831– 
838).  
 
j-Cypher Registry: Late and Very Late Stent 
Thrombosis Continue to Occur Without Attenuation 
up to 5 Years with Sirolimus-Eluting Stents  
 
Follow-up at 5 years was obtained in 12,812 patients 
undergoing implantation of sirolimus-eluting stent (SES). 
Cumulative incidence of definite stent thrombosis was 
low (30 day, 0.3%; 1 year, 0.6%; and 5 years, 1.6%). 
However, late and very late stent thrombosis continued to 
occur without attenuation up to 5 years after SES 
implantation (0.26%/y). Cumulative incidence of target 
lesion revascularization (TLR) within the first year was 
low (7.3%). However, late TLR beyond 1 year also 
continued to occur without attenuation up to 5 years 
(2.2%/y). Independent risk factors of stent thrombosis 
depended on time of its occurrence. For early thrombosis: 
acute coronary syndrome and target of proximal left 
anterior descending coronary artery; for late thrombosis: 
side-branch stenting, diabetes mellitus, and end-stage 
renal disease with or without hemodialysis; and for very 
late thrombosis: current smoking and total stent length 
>28 mm. The authors concluded that very late stent 
thrombosis and late TLR are continuous hazards, lasting 
at least up to 5 years after implantation of the first-





Everolimus Eluting Stent (EES) is Associated with a 
Lower Risk of Very Late Stent Thrombosis Compared 
with Early-Generation Drug-Eluting Stents (DES) 
 
The risk of stent thrombosis was assessed in a cohort 
of 12,339 patients receiving drug-eluting stents (DES) 
(3819 sirolimus-SES, 4308 paclitaxel-PES, 4212 
everolimus-EES). During follow-up of up to 4 years, the 
overall incidence of stent thrombosis was lower with EES 
(1.4 per 100 person-years) compared with SES (2.9; 
hazard ratio, 0.41; P<0.0001) and PES (4.4; hazard ratio, 
0.33; P<0.0001). The incidence rate per 100 person-years 
of early (0–30 days), late (31 days–1 year), and very late 
stent thrombosis amounted to 0.6, 0.1, and 0.6 among 
EES-treated patients; 1.0, 0.3, and 1.6 among SES-treated 
patients; and 1.3, 0.7, and 2.4 among PES-treated 
patients. Differences in favor of EES were most 
pronounced beyond 1 year. There was a lower risk of 
cardiac death or myocardial infarction with EES 
compared with PES directly related to the lower risk of 
stent thrombosis. The authors concluded that EES is 
associated with a lower risk of very late stent thrombosis 
compared with early-generation drug-eluting stents 
(Raeber L et al, Circulation 2012;125:1110-1121.) 
 
Risk of Malignant Arrhythmias in Symptomatic 
Patients with WPW Syndrome Remains Low  
 
Among 8575 symptomatic Wolff-Parkinson-White 
(WPW) patients with atrioventricular reentrant 
tachycardia (AVRT) referred for an electrophysiology 
study, 369 declined catheter ablation and were followed 
up. After a mean follow-up of 42+10 months, malignant 
arrhythmias developed in 29 patients, resulting in 
presyncope/ syncope (25 patients), hemodynamic 
collapse (3 patients), or cardiac arrest caused by 
ventricular fibrillation (1 patient). Of the remaining 340 
patients, 168 remained asymptomatic up to 5 years, and 
172 had benign recurrence, including sustained AVRT 
(132 patients) or atrial fibrillation (40 patients). 
Compared with subjects with no malignant arrhythmias, 
those with malignant arrhythmias more often exhibited 
multiple accessory pathways (P<0.001), showed shorter 
accessory-pathway effective refractory period (P<0.001) 
and AVRT triggering sustained pre-excited atrial 
fibrillation was more frequently inducible (P<0.001). The 
latter two variables were independent predictors of 
malignant arrhythmias. The authors concluded that 
symptomatic patients with WPW syndrome generally 
have a good outcome, and predictors of malignant 
arrhythmias are similar to those reported for 
asymptomatic patients with ventricular pre-excitation. 
(Pappone C et al, Circulation 2012;125:661-668).  
 
Observational, Propensity Score–matched Study: 
Percutaneous PFO Closure More Effective than 
Medical Treatment for the Secondary Prevention of 
Recurrent Cerebrovascular Events  
 
A total of 308 consecutive patients with 
cerebrovascular events presumably related to PFO 
underwent either percutaneous PFO closure (150 patients) 
or medical treatment (158 patients) and were followed up 
prospectively for up to 15 years (except for 7 who were 
lost at follow-up). Analysis of 103 propensity score–
matched pairs of patients showed that at a median follow-
up of 9 years recurrence was noted in 11 patients with 
PFO closure (11%) and 22 patients with medical 
treatment (21%; hazard ratio=0.43; P=0.033). The risk of 
all-cause (6% in both groups) and cardiovascular (3% in 
both groups) mortality was similar. The authors 
concluded that PFO closure was more effective than 
medical treatment for the secondary prevention of 
recurrent cerebrovascular events among patients with 
PFO-related transient ischemic attack or stroke (Wahl A 
et al, Circulation 2012;125:803-812).  
 
Important Review and Other Articles  
 
Closure of left atrial appendage (Landmesser U & 
Holmes DR, Eur Heart J 2012; 33:698-704), Secondary 
stroke prevention (Meier B et al, Eur Heart J 2012; 
33:705-713), Assessing risk of interventions in valvular 
heart disease (Rosenhek R et al, Eur Heart J 2012; 
33:822-828), Hypothermia therapy (Delhaye C et al, J 
Am Coll Cardiol 2012; 59:197–210), Role of AV node 
ablation in patients with CRT & AF (Ganesan AN et al, J 
Am Coll Cardiol 2012;59:719-726), Update on 
myocarditis (Kindermann I et al, J Am Coll Cardiol 
2012;59:779-792), Consensus standards for OCT 
(Tearney GJ et al, J Am Coll Cardiol 2012;59:1058-
1072), Expert consensus 2012 on TAVI (Holmes DR et 
al, J Am Coll Cardiol 2012;59:1200-1254), 
Antiarrhythmic drug therapy for AF (Zimetbaum P, 
Circulation 2012; 125:381-385), Atrial fibrillation in 
athletes (Turagam MK et al, Am J Cardiol 2012;109:296-
302), Epidemiology and genetics of sudden death (Deo R 
& Albert CM, Circulation 2012; 125:620-637), 
Management of atrial fibrillation in patients with 
structural heart disease (Darby AE & John P. DiMarco 
JP, Circulation 2012;125:945-957), Acute coronary 
events (Arbab-Zadeh A et al, Circulation 2012;125:1147-
1156), Mechanical circulatory support for advanced heart 
failure (Stewart GC & Givertz MM, Circulation 
2012;125:1304-1315), Sudden death from 
cardiomyopathies (Sen-Chowdhry S & McKenna WJ, 
Circulation 2012;125: 1563-1576).  
